<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34445116</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>16</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">8412</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22168412</ELocationID>
        <Abstract>
          <AbstractText>Erythropoietin-producing human hepatocellular receptors (EPHs) compose the largest known subfamily of receptor tyrosine kinases (RTKs). They bind and interact with the EPH family receptor interacting proteins (ephrins). EPHs/ephrins are implicated in a variety of physiological processes, as well as in cancer pathogenesis. With neoplastic disease remaining a leading cause of death world-wide, the development of novel biomarkers aiding in the field of diagnosis, prognosis, and disease monitoring is of utmost importance. A multitude of studies have proven the association between the expression of members of the EPH/ephrin system and various clinicopathological parameters, including disease stage, tumor histologic grade, and patients' overall survival. Besides their utilization in timely disease detection and assessment of outcome, EPHs/ephrins could also represent possible novel therapeutic targets. The aim of the current review of the literature was to present the existing data regarding the association between EPH/ephrin system expression and the clinical characteristics of malignant tumors.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pergaris</LastName>
            <ForeName>Alexandros</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-4960-672X</Identifier>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Danas</LastName>
            <ForeName>Eugene</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goutas</LastName>
            <ForeName>Dimitrios</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0003-1996-5884</Identifier>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sykaras</LastName>
            <ForeName>Alexandros G</ForeName>
            <Initials>AG</Initials>
            <Identifier Source="ORCID">0000-0002-2972-0138</Identifier>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soranidis</LastName>
            <ForeName>Angelos</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Theocharis</LastName>
            <ForeName>Stamatios</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D036342">Ephrins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036082">Receptor, EphA1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036342" MajorTopicYN="N">Ephrins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036082" MajorTopicYN="N">Receptor, EphA1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">EPHs</Keyword>
        <Keyword MajorTopicYN="N">biomarkers</Keyword>
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">diagnosis</Keyword>
        <Keyword MajorTopicYN="N">ephrins</Keyword>
        <Keyword MajorTopicYN="N">prognosis</Keyword>
        <Keyword MajorTopicYN="N">treatment</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34445116</ArticleId>
        <ArticleId IdType="pmc">PMC8395090</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms22168412</ArticleId>
        <ArticleId IdType="pii">ijms22168412</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21660</ArticleId>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Statistics—National Cancer Institute.  [(accessed on 13 June 2021)]; Available online:  https://www.cancer.gov/about-cancer/understanding/statistics.</Citation>
        </Reference>
        <Reference>
          <Citation>Rudno-Rudzińska J., Kielan W., Frejlich E., Kotulski K., Hap W., Kurnol K., Dzierżek P., Zawadzki M., Hałoń A. A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers. Chin. J. Cancer Res. 2017;29:303–312. doi: 10.21147/j.issn.1000-9604.2017.04.03.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21147/j.issn.1000-9604.2017.04.03</ArticleId>
            <ArticleId IdType="pmc">PMC5592818</ArticleId>
            <ArticleId IdType="pubmed">28947862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones D. Parallels of Resistance between Angiogenesis and Lymphangiogenesis Inhibition in Cancer Therapy. Cells. 2020;9:762.  doi: 10.3390/cells9030762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9030762</ArticleId>
            <ArticleId IdType="pmc">PMC7140636</ArticleId>
            <ArticleId IdType="pubmed">32244922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kou C.-T.J., Kandpal R.P. Differential Expression Patterns of Eph Receptors and Ephrin Ligands in Human Cancers. BioMed Res. Int. 2018;2018:7390104. doi: 10.1155/2018/7390104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/7390104</ArticleId>
            <ArticleId IdType="pmc">PMC5851329</ArticleId>
            <ArticleId IdType="pubmed">29682554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Wang L., Gu J.-W., Li B., Liu W.-P., Wang Y.-G., Zhang X., Zhen H.-N., Fei Z. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma. Tumor Biol. 2010;31:477–488. doi: 10.1007/s13277-010-0060-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-010-0060-6</ArticleId>
            <ArticleId IdType="pubmed">20571968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F., Park P.J., Lai W., Maher E., Chakravarti A., Durso L., Jiang X., Yu Y., Brosius A., Thomas M., et al.  A Genome-Wide Screen Reveals Functional Gene Clusters in the Cancer Genome and Identifies EphA2 as a Mitogen in Glioblastoma. Cancer Res. 2006;66:10815–10823. doi: 10.1158/0008-5472.CAN-06-1408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-1408</ArticleId>
            <ArticleId IdType="pubmed">17090523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suo F., Zhong B., Lu F., Dong Z. The combined use of EphA2/MMP-2 expression and MRI findings contributes to the determination of cerebral glioma grade. Oncol. Lett. 2019;18:5607–5613. doi: 10.3892/ol.2019.10912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.10912</ArticleId>
            <ArticleId IdType="pmc">PMC6788174</ArticleId>
            <ArticleId IdType="pubmed">31620202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Royet A., Broutier L., Coissieux M.-M., Malleval C., Gadot N., Maillet D., Gratadou-Hupon L., Bernet A., Nony P., Treilleux I., et al.  Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4. Oncotarget. 2017;8:23750–23759. doi: 10.18632/oncotarget.16077.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.16077</ArticleId>
            <ArticleId IdType="pmc">PMC5410341</ArticleId>
            <ArticleId IdType="pubmed">28423606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L.-F., Fokas E., Juricko J., You A., Rose F., Pagenstecher A., Engenhart-Cabillic R., Janko J. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer. 2008;8:79.  doi: 10.1186/1471-2407-8-79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-8-79</ArticleId>
            <ArticleId IdType="pmc">PMC2292196</ArticleId>
            <ArticleId IdType="pubmed">18366728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng L., Nakada M., Furuyama N., Sabit H., Furuta T., Hayashi Y., Takino T., Dong Y., Sato H., Sai Y., et al.  Ligand-dependent EphB1 signaling suppresses glioma invasion and correlates with patient survival. Neuro Oncol. 2013;15:1710–1720. doi: 10.1093/neuonc/not128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/not128</ArticleId>
            <ArticleId IdType="pmc">PMC3829595</ArticleId>
            <ArticleId IdType="pubmed">24121831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu Y., He S., Fu J., Li G., Xu R., Lu H., Deng J. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients. Clin. Transl. Oncol. 2012;14:214–220. doi: 10.1007/s12094-012-0786-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-012-0786-2</ArticleId>
            <ArticleId IdType="pubmed">22374425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao Z., Zhu F., Song K., Zhang H., Liu K., Shang Z. EphA2/EphrinA1 mRNA Expression and Protein Production in Adenoid Cystic Carcinoma of Salivary Gland. J. Oral Maxillofac. Surg. 2013;71:869–878. doi: 10.1016/j.joms.2012.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.joms.2012.10.026</ArticleId>
            <ArticleId IdType="pubmed">23298804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukai J., Fujita K., Yamoto T., Sasaki T., Uematsu Y., Nakao N. Intracranial extension of adenoid cystic carcinoma: Potential involvement of EphA2 expression and epithelial-mesenchymal transition in tumor metastasis: A case report. BMC Res. Notes. 2014;7:131.  doi: 10.1186/1756-0500-7-131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-0500-7-131</ArticleId>
            <ArticleId IdType="pmc">PMC3975335</ArticleId>
            <ArticleId IdType="pubmed">24606764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karidis N.P., Giaginis C., Tsourouflis G., Alexandrou P., Delladetsima I., Theocharis S. Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: An immunohistochemical study. Med. Sci. Monit. 2011;17:BR257–BR265. doi: 10.12659/MSM.881929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12659/MSM.881929</ArticleId>
            <ArticleId IdType="pmc">PMC3560523</ArticleId>
            <ArticleId IdType="pubmed">21873938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin C., Cau W., Zhang Y., Mghanga F.P., Lan X., Gao Z., An R. Correlation of Clinicopathological Features and Expression of Molecular Markers With Prognosis After 131I Treatment of Differentiated Thyroid Carcinoma. Clin. Nucl. Med. 2012;37:e40–e46. doi: 10.1097/RLU.0b013e31823905e4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RLU.0b013e31823905e4</ArticleId>
            <ArticleId IdType="pubmed">22310269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giaginis C., Alexandrou P., Poulaki E., Delladetsima I., Troungos C., Patsouris E., Theocharis S. Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions. Pathol. Oncol. Res. 2015;22:269–275. doi: 10.1007/s12253-014-9879-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12253-014-9879-2</ArticleId>
            <ArticleId IdType="pubmed">26220827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma G.K., Dhillon V.K., Masood R., Maceri D.R. Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study. Head Neck. 2014;37:964–969. doi: 10.1002/hed.23694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hed.23694</ArticleId>
            <ArticleId IdType="pubmed">24634162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kebebew E., Peng M., Reiff E., Duh Q.-Y., Clark O.H., McMillan A. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. Surgery. 2005;138:1102–1110. doi: 10.1016/j.surg.2005.05.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2005.05.025</ArticleId>
            <ArticleId IdType="pubmed">16360397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giaginis C., Tsoukalas N., Bournakis E., Alexandrou P., Kavantzas N., Patsouris E., Theocharis S. Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. BMC Clin. Pathol. 2014;14:8.  doi: 10.1186/1472-6890-14-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1472-6890-14-8</ArticleId>
            <ArticleId IdType="pmc">PMC4234387</ArticleId>
            <ArticleId IdType="pubmed">24495444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efazat G., Novak M., Kaminskyy V.O., De Petris L., Kanter L., Juntti T., Bergman P., Zhivotovsky B., Lewensohn R., Hååg P., et al.  Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer. Oncotarget. 2016;7:60332–60347. doi: 10.18632/oncotarget.11219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.11219</ArticleId>
            <ArticleId IdType="pmc">PMC5312387</ArticleId>
            <ArticleId IdType="pubmed">27533087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa M., Miyahara R., Sonobe M., Horiuchi M., Mennju T., Nakayama E., Kobayashi M., Kikuchi R., Kitamura J., Imamura N., et al.  Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer. 2012;76:431–438. doi: 10.1016/j.lungcan.2011.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2011.12.004</ArticleId>
            <ArticleId IdType="pubmed">22236865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Peng Q., Sai B., Zheng L., Xu J., Yin N., Feng X., Xiang J. Ligand-independent EphB1 signaling mediates TGF-β-activated CDH2 and promotes lung cancer cell invasion and migration. J. Cancer. 2020;11:4123–4131. doi: 10.7150/jca.44576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.44576</ArticleId>
            <ArticleId IdType="pmc">PMC7196256</ArticleId>
            <ArticleId IdType="pubmed">32368295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao C., Wang A., Lu F., Chen H., Fu P., Zhao X., Chen H. Overexpression of junctional adhesion molecule-A and EphB2 predicts poor survival in lung adenocarcinoma patients. Tumor Biol. 2017;39:1010428317691000. doi: 10.1177/1010428317691000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1010428317691000</ArticleId>
            <ArticleId IdType="pubmed">28231727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Sun Y., Wang X., Wang J., Zhu Y. The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: A high level of the EphB4 protein is associated with lymph node metastasis. Int. J. Clin. Exp. Pathol. 2019;12:3447–3452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6949841</ArticleId>
            <ArticleId IdType="pubmed">31934189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rud A.K., Boye K., Øijordsbakken M., Lund-Iversen M., Halvorsen A.R., Solberg S.K., Berge G., Helland A., Brustugun O.T., Mælandsmo G.M. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013;13:540.  doi: 10.1186/1471-2407-13-540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-13-540</ArticleId>
            <ArticleId IdType="pmc">PMC3830440</ArticleId>
            <ArticleId IdType="pubmed">24215488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husa A.-M., Magić Z., Larsson M., Fornander T., Pérez-Tenorio G. EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer. Oncotarget. 2016;7:21362–21380. doi: 10.18632/oncotarget.7246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7246</ArticleId>
            <ArticleId IdType="pmc">PMC5008291</ArticleId>
            <ArticleId IdType="pubmed">26870995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brantley-Sieders D.M., Jiang A., Sarma K., Badu-Nkansah A., Walter D.L., Shyr Y., Chen J. Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome. PLoS ONE. 2011;6:e24426.  doi: 10.1371/journal.pone.0024426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0024426</ArticleId>
            <ArticleId IdType="pmc">PMC3174170</ArticleId>
            <ArticleId IdType="pubmed">21935409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hachim I.Y., Villatoro M., Canaff L., Hachim M., Boudreault J., Haiub H., Ali S., Lebrun J.-J. Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration. Sci. Rep. 2017;7:14976. doi: 10.1038/s41598-017-14549-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-14549-9</ArticleId>
            <ArticleId IdType="pmc">PMC5670207</ArticleId>
            <ArticleId IdType="pubmed">29101386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mu X., Huang O., Jiang M., Xie Z., Chen D., Zhang X. Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3554 patients. Oncol. Lett. 2019;18:742–750. doi: 10.3892/ol.2019.10363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2019.10363</ArticleId>
            <ArticleId IdType="pmc">PMC6540016</ArticleId>
            <ArticleId IdType="pubmed">31289549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Q., Suo Z., Risberg B., Karlsson M.G., Villman K., Nesland J.M. Expression of Ephb2 And Ephb4 in Breast Carci-noma. Pathol. Oncol. Res. 2004;10:26–33. doi: 10.1007/BF02893405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02893405</ArticleId>
            <ArticleId IdType="pubmed">15029258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magic Z., Perez-Tenorio G. Ephrin-B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis-free survival in breast cancer. Int. J. Oncol. 2019;55:1275–1286. doi: 10.3892/ijo.2019.4892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2019.4892</ArticleId>
            <ArticleId IdType="pmc">PMC6831205</ArticleId>
            <ArticleId IdType="pubmed">31638179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernández-Nogueira P., Bragado P., Almendro V., Ametller E., Rios J., Choudhury S., Mancino M., Gascón P. Differential expression of neurogenes among breast cancer subtypes identifies high risk pa-tients.  [(accessed on 2 August 2021)];Oncotarget. 2015 7:5313–5326. doi: 10.18632/oncotarget.6543. Available online:  www.impactjournals.com/oncotarget.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.6543</ArticleId>
            <ArticleId IdType="pmc">PMC4868688</ArticleId>
            <ArticleId IdType="pubmed">26673618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin H., Lu C., Tang Y., Wang H., Wang H., Wang J. Enhanced expression of EphrinB1 is associated with lymph node metastasis and poor prognosis in breast cancer. Cancer Biomark. 2013;13:261–267. doi: 10.3233/CBM-130356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/CBM-130356</ArticleId>
            <ArticleId IdType="pubmed">24240587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafner C., Becker B., Landthaler M., Vogt T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod. Pathol. 2006;19:1369–1377. doi: 10.1038/modpathol.3800660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.3800660</ArticleId>
            <ArticleId IdType="pubmed">16862074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straume O., Akslen L.A. Importance of Vascular Phenotype by Basic Fibroblast Growth Factor, and Influence of the Angiogenic Factors Basic Fibroblast Growth Factor/Fibroblast Growth Factor Receptor-1 and Ephrin-A1/EphA2 on Mela-noma Progression. Am. J. Pathol. 2002;160:1009–1019. doi: 10.1016/S0002-9440(10)64922-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)64922-X</ArticleId>
            <ArticleId IdType="pmc">PMC1867162</ArticleId>
            <ArticleId IdType="pubmed">11891198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schauer M.C., Stoecklein N.H., Theisen J., Kröpil F., Baldus S., Hoelscher A., Feith M., Bölke E., Matuschek C., Budach W., et al.  The simultaneous expression of both ephrin B3 receptor and E-cadherin in Barrett‘s adenocarcinoma is associated with favorable clinical staging. Eur. J. Med. Res. 2012;17:10. doi: 10.1186/2047-783X-17-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2047-783X-17-10</ArticleId>
            <ArticleId IdType="pmc">PMC3471084</ArticleId>
            <ArticleId IdType="pubmed">22583970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liersch-Löhn B., Slavova N., Buhr H.J., Bennani-Baiti I.M. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers. Int. J. Cancer. 2015;138:1220–1231. doi: 10.1002/ijc.29865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29865</ArticleId>
            <ArticleId IdType="pubmed">26414866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan W.-J., Ge J., Chen Z.-K., Wu S.-B., Shen H., Yang P., Hu B., Zhang G.-W., Chen Z.-H. Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients. Dig. Dis. Sci. 2008;54:2410–2417. doi: 10.1007/s10620-008-0649-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-008-0649-4</ArticleId>
            <ArticleId IdType="pubmed">19101799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura R., Kataoka H., Sato N., Kanamori M., Ihara M., Igarashi H., Ravshanov S., Wang Y.-J., Li Z.-Y., Shimamura T., et al.  EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 2005;96:42–47. doi: 10.1111/j.1349-7006.2005.00007.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2005.00007.x</ArticleId>
            <ArticleId IdType="pubmed">15649254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong H.N., Won Y.J., Shim J.H., Kim H.J., Han S.H., Kim B.S., Kim H.S. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner. J. Cancer Res. Clin. Oncol. 2018;144:1649–1663. doi: 10.1007/s00432-018-2683-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-018-2683-8</ArticleId>
            <ArticleId IdType="pubmed">29948146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oki M., Yamamoto H., Taniguchi H., Adachi Y., Imai K., Shinomura Y. Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J. Gastroenterol. 2008;14:5650–5656. doi: 10.3748/wjg.14.5650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.14.5650</ArticleId>
            <ArticleId IdType="pmc">PMC2748198</ArticleId>
            <ArticleId IdType="pubmed">18837080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Zhou N., Li P., Wu H., Wang Q., Gao X., Wang X., Huang J. EphA8 acts as an oncogene and contributes to poor prognosis in gastric cancer via regulation of ADAM10. J. Cell. Physiol. 2019;234:20408–20419. doi: 10.1002/jcp.28642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.28642</ArticleId>
            <ArticleId IdType="pubmed">31026069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kikuchi S., Kaibe N., Morimoto K., Fukui H., Niwa H., Maeyama Y., Takemura M., Matsumoto M., Nakamori S., Miwa H., et al.  Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer. Gastric Cancer. 2014;18:485–494. doi: 10.1007/s10120-014-0390-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10120-014-0390-y</ArticleId>
            <ArticleId IdType="pubmed">24908114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kataoka H., Tanaka M., Kanamori M., Yoshii S., Ihara M., Wang Y.-J., Song J.-P., Li Z.-Y., Arai H., Otsuki Y., et al.  Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J. Cancer Res. Clin. Oncol. 2002;128:343–348. doi: 10.1007/s00432-002-0355-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00432-002-0355-0</ArticleId>
            <ArticleId IdType="pubmed">12136247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J., Bin Xu B., Xu G., Zhang X., Yang X., Wang J. Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor. Cancer Biomark. 2017;19:241–248. doi: 10.3233/CBM-160256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/CBM-160256</ArticleId>
            <ArticleId IdType="pubmed">28453458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rawla P., Sunkara T., Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Gastroenterol. Rev. 2019;14:89–103. doi: 10.5114/pg.2018.81072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/pg.2018.81072</ArticleId>
            <ArticleId IdType="pmc">PMC6791134</ArticleId>
            <ArticleId IdType="pubmed">31616522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herath N.I., Spanevello M.D., Doecke J.D., Smith F.M., Pouponnot C., Boyd A.W. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur. J. Cancer. 2012;48:753–762. doi: 10.1016/j.ejca.2011.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2011.07.003</ArticleId>
            <ArticleId IdType="pubmed">21852108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herath N.I., Doecke J., Spanevello M.D., Leggett B., Boyd A.W. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br. J. Cancer. 2009;100:1095–1102. doi: 10.1038/sj.bjc.6604970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604970</ArticleId>
            <ArticleId IdType="pmc">PMC2670002</ArticleId>
            <ArticleId IdType="pubmed">19277044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kataoka H., Igarashi H., Kanamori M., Ihara M., Wang J.-D., Wang Y.-J., Li Z.-Y., Shimamura T., Kobayashi T., Maruyama K., et al.  Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004;95:136–141. doi: 10.1111/j.1349-7006.2004.tb03194.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2004.tb03194.x</ArticleId>
            <ArticleId IdType="pubmed">14965363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M., Yang C., Liu X., Yuan L., Zhang F., Wang M., Miao D., Gu X., Jiang S., Cui B., et al.  EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways. Cancer Lett. 2016;383:195–203. doi: 10.1016/j.canlet.2016.10.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2016.10.004</ArticleId>
            <ArticleId IdType="pubmed">27721017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T.-H., Chang J.-L., Ho J.-Y., Wu H.-C., Chen T.-C. EphrinA5 suppresses colon cancer development by negatively regulating epidermal growth factor receptor stability. FEBS J. 2011;279:251–263. doi: 10.1111/j.1742-4658.2011.08419.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-4658.2011.08419.x</ArticleId>
            <ArticleId IdType="pubmed">22074469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W., Ahmad S.A., Jung Y.D., Reinmuth N., Fan B.S.F., Bucana C.D., Ellis L.M. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer. 2002;94:934–939. doi: 10.1002/cncr.10122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.10122</ArticleId>
            <ArticleId IdType="pubmed">11920461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo D.L., Tsui W.Y., Chan A.S., Ho C., Leung S.Y., Zhang J., Yuen S.T., Ji J., Chen X. Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis. 2005;27:454–464. doi: 10.1093/carcin/bgi259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgi259</ArticleId>
            <ArticleId IdType="pubmed">16272170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drucker A., Arnason T., Sen R.Y., Aljawad M., Thompson K., Huang W.-Y. Ephrin B2 Receptor and Microsatellite Status in Lymph Node-Positive Colon Cancer Survival. Transl. Oncol. 2013;6:520–527. doi: 10.1593/tlo.13385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/tlo.13385</ArticleId>
            <ArticleId IdType="pmc">PMC3799194</ArticleId>
            <ArticleId IdType="pubmed">24151532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jubb A.M., Zhong F., Bheddah S., Grabsch H.I., Frantz G.D., Mueller W., Kavi V., Quirke P., Polakis P., Koeppen H. EphB2 is a Prognostic Factor in Colorectal Cancer. Clin. Cancer Res. 2005;11:5181–5187. doi: 10.1158/1078-0432.CCR-05-0143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-05-0143</ArticleId>
            <ArticleId IdType="pubmed">16033834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lugli A., Spichtin H., Maurer R., Mirlacher M., Kiefer J., Huusko P., Azorsa D., Terracciano L., Sauter G., Kallioniemi O., et al.  EphB2 Expression across 138 Human Tumor Types in a Tissue Microarray: High Levels of Expression in Gastrointestinal Cancers. Clin. Cancer Res. 2005;11:6450–6458. doi: 10.1158/1078-0432.CCR-04-2458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-2458</ArticleId>
            <ArticleId IdType="pubmed">16166419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batlle E., Bacani J., Begthel H., Jonkheer S., Gregorieff A., Van De Born M., Malats N., Sancho E., Boon E., Pawson T., et al.  EphB receptor activity suppresses colorectal cancer progression. Nat. Cell Biol. 2005;435:1126–1130. doi: 10.1038/nature03626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature03626</ArticleId>
            <ArticleId IdType="pubmed">15973414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang B.G., Kim H.S., Bae J.M., Kim W.H., Hyun C.L., Kang G.H. Expression Profile and Prognostic Significance of EPHB3 in Colorectal Cancer. Biomolecules. 2020;10:602.  doi: 10.3390/biom10040602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom10040602</ArticleId>
            <ArticleId IdType="pmc">PMC7226026</ArticleId>
            <ArticleId IdType="pubmed">32294981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv J., Xia Q., Wang J., Shen Q., Zhang J., Zhou X. EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer. Exp. Mol. Pathol. 2016;100:402–408. doi: 10.1016/j.yexmp.2016.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexmp.2016.03.011</ArticleId>
            <ArticleId IdType="pubmed">27072105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iida H., Honda M., Kawai H.F., Yamashita T., Shirota Y., Wang B.-C., Miao H., Kaneko S. Ephrin-A1 expression contributes to the malignant characteristics of -fetoprotein producing hepatocellular carcinoma. Gut. 2005;54:843–851. doi: 10.1136/gut.2004.049486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.2004.049486</ArticleId>
            <ArticleId IdType="pmc">PMC1774523</ArticleId>
            <ArticleId IdType="pubmed">15888795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui X.-D., Lee M.-J., Yu G.-R., Kim I.-H., Yu H.-C., Song E.-Y., Kim D.-G. EFNA1 ligand and its receptor EphA2: Potential biomarkers for hepatocellular carcinoma. Int. J. Cancer. 2009;126:940–949. doi: 10.1002/ijc.24798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.24798</ArticleId>
            <ArticleId IdType="pubmed">19642143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wada H., Yamamoto H., Kim C., Uemura M., Akita H., Tomimaru Y., Hama N., Kawamoto K., Kobayashi S., Eguchi H., et al.  Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma. Int. J. Oncol. 2014;45:1051–1058. doi: 10.3892/ijo.2014.2519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2014.2519</ArticleId>
            <ArticleId IdType="pubmed">24969670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Zhang M., Ping F., Liu H., Sun J., Wang Y., Shen A., Ding J., Geng M. Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology. 2019;69:573–586. doi: 10.1002/hep.29792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29792</ArticleId>
            <ArticleId IdType="pmc">PMC6586030</ArticleId>
            <ArticleId IdType="pubmed">29356025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T.-H., Ng K.-F., Yeh T.-S., Wang Y.-L., Liang K.-H., Yeh C.-T., Chen T.-C. Peritumoral Small EphrinA5 Isoform Level Predicts the Postoperative Survival in Hepatocellular Carcinoma. PLoS ONE. 2012;7:e41749.  doi: 10.1371/journal.pone.0041749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0041749</ArticleId>
            <ArticleId IdType="pmc">PMC3408466</ArticleId>
            <ArticleId IdType="pubmed">22860012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng Y., Wei J., Zhang Y., Gao X., Wang Z., Yang J., Yan S., Zhu Y., Zhang Z., Xu D., et al.  Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma. Int. J. Cancer. 2018;144:2440–2452. doi: 10.1002/ijc.31979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.31979</ArticleId>
            <ArticleId IdType="pubmed">30412282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khansaard W., Techasen A., Namwat N., Yongvanit P., Khuntikeo N., Puapairoj A., Loilome W. Increased EphB2 expression predicts cholangiocarcinoma metastasis. Tumor Biol. 2014;35:10031–10041. doi: 10.1007/s13277-014-2295-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-014-2295-0</ArticleId>
            <ArticleId IdType="pubmed">25012246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu F., Dai S.-N., Xu D.-L., Hou C.-Q., Liu T.-T., Chen Q.-Y., Wu J.-L., Miao Y. EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Biomed. Pharmacother. 2020;125:109972. doi: 10.1016/j.biopha.2020.109972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2020.109972</ArticleId>
            <ArticleId IdType="pubmed">32036221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toma M.I., Erdmann K., Diezel M., Meinhardt M., Zastrow S., Fuessel S., Wirth M.P., Baretton G.B. Lack of Ephrin Receptor A1 Is a Favorable Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. PLoS ONE. 2014;9:e102262.  doi: 10.1371/journal.pone.0102262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0102262</ArticleId>
            <ArticleId IdType="pmc">PMC4099180</ArticleId>
            <ArticleId IdType="pubmed">25025847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Xu H., Cao G., Wu Z., Wang J. Loss of EphA3 Protein Expression Is Associated With Advanced TNM Stage in Clear-Cell Renal Cell Carcinoma. Clin. Genitourin. Cancer. 2017;15:e169–e173. doi: 10.1016/j.clgc.2016.07.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2016.07.028</ArticleId>
            <ArticleId IdType="pubmed">27591824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Özgür E., Heidenreich A., Dagtekin O., Engelmann U., Bloch W. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue. Urol. Oncol. Semin. Orig. Investig. 2011;29:78–84. doi: 10.1016/j.urolonc.2008.12.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.urolonc.2008.12.020</ArticleId>
            <ArticleId IdType="pubmed">19272799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham S., Knapp D.W., Cheng L., Snyder P.W., Mittal S.K., Bangari D.S., Kinch M., Wu L., Dhariwal J., Mohammed S.I. Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder. Clin. Cancer Res. 2006;12:353–360. doi: 10.1158/1078-0432.CCR-05-1505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-05-1505</ArticleId>
            <ArticleId IdType="pubmed">16428472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Choi W.W., Yan R., Yu H., Krasnoperov V., Kumar S.R., Schuckman A., Klumpp D.J., Pan C.-X., Quinn D., et al.  The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder. PLoS ONE. 2014;9:e105326.  doi: 10.1371/journal.pone.0105326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105326</ArticleId>
            <ArticleId IdType="pmc">PMC4141800</ArticleId>
            <ArticleId IdType="pubmed">25148033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oweida A., Bhatia S., Hirsch K., Calame D., Griego A., Keysar S., Pitts T., Sharma J., Eckhardt G., Jimeno A., et al.  Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors. Mol. Carcinog. 2016;56:1189–1196. doi: 10.1002/mc.22574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22574</ArticleId>
            <ArticleId IdType="pmc">PMC5939940</ArticleId>
            <ArticleId IdType="pubmed">27649287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S., Zhu Y., Ma C., Qiu Z., Zhang X., Kang Z., Wu Z., Wang H., Xu X., Zhang H., et al.  Downregulation of EphA5 by promoter methylation in human prostate cancer. BMC Cancer. 2015;15:18.  doi: 10.1186/s12885-015-1025-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-015-1025-3</ArticleId>
            <ArticleId IdType="pmc">PMC4307617</ArticleId>
            <ArticleId IdType="pubmed">25609195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S., Ma Y., Xie C., Wu Z., Kang Z., Fang Z., Su B., Guan M. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer pro-gression.  [(accessed on 2 August 2021)];Oncotarget. 2015 6:22587–22597. doi: 10.18632/oncotarget.4088. Available online:  www.impactjournals.com/oncotarget/</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.4088</ArticleId>
            <ArticleId IdType="pmc">PMC4673184</ArticleId>
            <ArticleId IdType="pubmed">26041887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herath N.I., Spanevello M.D., Sabesan S., Newton T., Cummings M., Duffy S., Lincoln D., Boyle G., Parsons P.G., Boyd A.W. Over-expression of Eph and ephrin genes in advanced ovarian cancer: Ephrin gene expression correlates with shortened survival. BMC Cancer. 2006;6:144.  doi: 10.1186/1471-2407-6-144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-6-144</ArticleId>
            <ArticleId IdType="pmc">PMC1501040</ArticleId>
            <ArticleId IdType="pubmed">16737551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han L., Dong Z., Qiao Y., Kristensen G.B., Holm R., Nesland J.M., Suo Z. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol. Oncol. 2005;99:278–286. doi: 10.1016/j.ygyno.2005.06.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2005.06.036</ArticleId>
            <ArticleId IdType="pubmed">16061279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Wang X., Wei X., Wang J. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma. J. Ovarian Res. 2016;9:83. doi: 10.1186/s13048-016-0292-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13048-016-0292-1</ArticleId>
            <ArticleId IdType="pmc">PMC5123222</ArticleId>
            <ArticleId IdType="pubmed">27887627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X., Xu Y., Jin Q., Wang W., Zhang S., Wang X., Zhang Y., Xu X., Huang J. EphA8 is a prognostic marker for epithelial ovarian cancer. Oncotarget. 2016;7:20801–20809. doi: 10.18632/oncotarget.8018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8018</ArticleId>
            <ArticleId IdType="pmc">PMC4991493</ArticleId>
            <ArticleId IdType="pubmed">26989075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao W., Zhang Q., Wang Y. EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas. APMIS. 2017;125:122–127. doi: 10.1111/apm.12646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/apm.12646</ArticleId>
            <ArticleId IdType="pubmed">28120491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam S.M., Fujimoto J., Jahan I., Sato E., Tamaya T. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br. J. Cancer. 2008;98:845–851. doi: 10.1038/sj.bjc.6604216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604216</ArticleId>
            <ArticleId IdType="pmc">PMC2259170</ArticleId>
            <ArticleId IdType="pubmed">18231102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellvi J., García-Jiménez A., de la Torre J., Hernandez J., Gil-Moreno A., Xercavins J., Cajal S.R.Y. Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. Hum. Pathol. 2006;37:883–889. doi: 10.1016/j.humpath.2006.02.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2006.02.021</ArticleId>
            <ArticleId IdType="pubmed">16784989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamat A.A., Coffey D., Merritt W.M., Nugent E., Urbauer D., Lin Y.G., Edwards C., Broaddus R., Coleman R.L., Sood A.K. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009;115:2684–2692. doi: 10.1002/cncr.24335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.24335</ArticleId>
            <ArticleId IdType="pmc">PMC3139331</ArticleId>
            <ArticleId IdType="pubmed">19396818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alam S., Fujimoto J., Jahan I., Sato E., Tamaya T. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers. Ann. Oncol. 2006;18:485–490. doi: 10.1093/annonc/mdl414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdl414</ArticleId>
            <ArticleId IdType="pubmed">17108150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong L.-D., Cheng X.-L., Zhou L., Huang Q., Li J.-C., Yi C.-J. Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma. Oncol. Lett. 2017;13:2109–2114. doi: 10.3892/ol.2017.5698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.5698</ArticleId>
            <ArticleId IdType="pmc">PMC5403707</ArticleId>
            <ArticleId IdType="pubmed">28454369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu D., Suo Z., Kristensen G.B., Li S., Troen G., Holm R., Nesland J.M. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol. Oncol. 2004;94:312–319. doi: 10.1016/j.ygyno.2004.05.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2004.05.019</ArticleId>
            <ArticleId IdType="pubmed">15297167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holm R., Van de Putte G., Suo Z., Lie A.K., Kristensen G.B. Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int. J. Med. Sci. 2008;5:121–126. doi: 10.7150/ijms.5.121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijms.5.121</ArticleId>
            <ArticleId IdType="pmc">PMC2424178</ArticleId>
            <ArticleId IdType="pubmed">18566674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Q., Liu W., Cai J., Li M., Gao Y., Lin W., Li Z. EphB2 promotes cervical cancer progression by inducing epithelial-mesenchymal transition. Hum. Pathol. 2014;45:372–381. doi: 10.1016/j.humpath.2013.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2013.10.001</ArticleId>
            <ArticleId IdType="pubmed">24439224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S., Jiang T., Liang M. Expression of Eph B4 and Ephrin B2 in cervical cancer tissues and angiogenesis. Int. J. Gynecol. Obstet. 2007;96:46–47. doi: 10.1016/j.ijgo.2006.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijgo.2006.08.017</ArticleId>
            <ArticleId IdType="pubmed">17196593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Megiorni F., Gravina G.L., Camero S., Ceccarelli S., Del Fattore A., Desiderio V., Papaccio F., McDowell H.P., Shukla R., Pizzuti A., et al.  Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells. J. Hematol. Oncol. 2017;10:161. doi: 10.1186/s13045-017-0530-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-017-0530-z</ArticleId>
            <ArticleId IdType="pmc">PMC6389084</ArticleId>
            <ArticleId IdType="pubmed">28985758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Randolph M.E., Cleary M.M., Bajwa Z., Svalina M.N., Young M.C., Mansoor A., Kaur P., Bult C.J., Goros M.W., Michalek J.E., et al.  EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma. PLoS ONE. 2017;12:e0183161.  doi: 10.1371/journal.pone.0183161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0183161</ArticleId>
            <ArticleId IdType="pmc">PMC5560593</ArticleId>
            <ArticleId IdType="pubmed">28817624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang X.X., Zhao H., Robinson M.E., Cohen B., Cnaan A., London W., Cohn S., Cheung N.-K.V., Brodeur G.M., Evans A.E., et al.  Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc. Natl. Acad. Sci. USA. 2000;97:10936–10941. doi: 10.1073/pnas.190123297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.190123297</ArticleId>
            <ArticleId IdType="pmc">PMC27127</ArticleId>
            <ArticleId IdType="pubmed">10984508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chetcuti A., Aktas S., Mackie N., Ulger C., Toruner G., Alkan M., Catchpoole D. Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumors. Pediatr. Blood Cancer. 2011;57:950–957. doi: 10.1002/pbc.23003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.23003</ArticleId>
            <ArticleId IdType="pubmed">21387540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes P.W., Vail M.E., Gan H.K., Scott A.M. Antibody Targeting of Eph Receptors in Cancer. Pharm. 2020;13:88.  doi: 10.3390/ph13050088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph13050088</ArticleId>
            <ArticleId IdType="pmc">PMC7281212</ArticleId>
            <ArticleId IdType="pubmed">32397088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lodola A., Giorgio C., Incerti M., Zanotti I., Tognolini M. Targeting Eph/ephrin system in cancer therapy. Eur. J. Med. Chem. 2017;142:152–162. doi: 10.1016/j.ejmech.2017.07.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2017.07.029</ArticleId>
            <ArticleId IdType="pubmed">28780190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Khoueiry A., Gitlitz B., Cole S., Tsao-Wei D., Goldkorn A., Quinn D., Nieva J., Dorff T., Oswald M., Berg J., et al.  A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) Eur. J. Cancer. 2016;69:S11. doi: 10.1016/S0959-8049(16)32623-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0959-8049(16)32623-5</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
